Merck & Co. Stock

$80.69

0.40% day before yesterday

NYSE, Aug 08, 10:09 pm CET

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Merck & Co. Stock price

$80.69

+3.54 4.59% 5Y

NYSE, Closing price Fri, Aug 08 2025

+0.32 0.40%

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$201.5b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

12.4 | 9.0

P/S

3.2 | 3.1

EV/Sales

- | -

EV/FCF

P/B

Dividends

DPS

$3.12

Yield 1Y | 5Y

3.9% | 3.0%

Growth 1Y | 5Y

5.4% | 7.7%

Payout 1Y | 3Y

46.3% | 70.5%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$63.6b | $65.6b

EBITDA

- | $30.3b

EBIT

$23.9b | $27.2b

Net Income

$16.4b | -

Free Cash Flow

Growth (TTM | estimate)

Revenue

1.8% | 2.3%

EBITDA

- | 5.4%

EBIT

1.9% | 12.2%

Net Income

19.4% | -

Free Cash Flow

Financial Health

Equity Ratio

39.6%

Return on Equity

37.0%

ROCE

ROIC

Debt/Equity

EPS

$6.5

FCF per Share

Short interest

1.3%

Employees

74k

Rev per Employee

$870.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

32 Analysts have issued a Merck & Co. forecast:

19x Buy

59%

13x Hold

41%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Merck & Co. forecast:

Buy

59%

Hold

41%

Analyst Estimates with Stock Price Targets

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	63,616 63,616	2% 2% 100%
- Direct Costs	13,794 13,794	9% 9% 22%
Gross Profit	49,822 49,822	5% 5% 78%
- Selling and Administrative Expenses	10,733 10,733	3% 3% 17%
- Research and Development Expense	15,221 15,221	13% 13% 24%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	23,868 23,868	2% 2% 38%
Net Profit	16,406 16,406	19% 19% 26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Merck & Co. Stock News

Positive

Seeking Alpha

●

2 days ago

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbac...

Neutral

Seeking Alpha

●

4 days ago

Stock Picks From Seeking Alpha's July 2025 New Analysts

In July, Seeking Alpha welcomed 44 new analysts. This article introduces them and showcases some of their top picks. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bearish views on Netflix, Wayfair, and Capri Holdings, while our analysts were bullis...

Positive

The Motley Fool

●

4 days ago

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The premise makes enough sense on the surface. Not only does a higher dividend yield mean more income per invested dollar, it may also mean the stock in question is undervalued and ripe for a rebound.

More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office	United States
CEO	Robert Davis
Employees	74,000
Founded	1891
Website	www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now